Compared with non-users, SGLT2-i users were younger and had a higher prevalence of diabetes and dyslipidemia, a history of peripheral artery disease, previous myocardial infarction, and previous PCI, and they had a shorter hospital stay (Table 1). Here, SLC5A2 is linked to peripheral arterial disease.